newsfilter
← Latest News
PR Newswire·

First Patient Enrolled into U.S. Phase 3 Neurotrophic Keratitis Clinical Trial with RGN-259

ROCKVILLE, Md., April 13, 2023 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB:RGRX) ("RegeneRx" or "Company"), a clinical-stage drug development company focused on tissue protection, repair, and